Back to Search
Start Over
A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
- Source :
- Molecular Cancer Therapeutics. 20:1966-1976
- Publication Year :
- 2021
- Publisher :
- American Association for Cancer Research (AACR), 2021.
-
Abstract
- Lung cancers harboring mesenchymal-to-epithelial transition factor (MET) genetic alterations, such as exon 14 skipping mutations or high-level gene amplification, respond well to MET-selective tyrosine kinase inhibitors (TKI). However, these agents benefit a relatively small group of patients (4%–5% of lung cancers), and acquired resistance limits response durability. An antibody–drug conjugate (ADC) targeting MET might enable effective treatment of MET-overexpressing tumors (approximately 25% of lung cancers) that do not respond to MET targeted therapies. Using a protease-cleavable linker, we conjugated a biparatopic METxMET antibody to a maytansinoid payload to generate a MET ADC (METxMET-M114). METxMET-M114 promotes substantial and durable tumor regression in xenografts with moderate to high MET expression, including models that exhibit innate or acquired resistance to MET blockers. Positron emission tomography (PET) studies show that tumor uptake of radiolabeled METxMET antibody correlates with MET expression levels and METxMET-M114 efficacy. In a cynomolgus monkey toxicology study, METxMET-M114 was well tolerated at a dose that provides circulating drug concentrations that are sufficient for maximal antitumor activity in mouse models. Our findings suggest that METxMET-M114, which takes advantage of the unique trafficking properties of our METxMET antibody, is a promising candidate for the treatment of MET-overexpressing tumors, with the potential to address some of the limitations faced by the MET function blockers currently in clinical use.
- Subjects :
- Male
Drug
Cancer Research
Antibody-drug conjugate
Immunoconjugates
Lung Neoplasms
media_common.quotation_subject
Apoptosis
Mice, SCID
Maytansinoid
Mice
chemistry.chemical_compound
Exon
Carcinoma, Non-Small-Cell Lung
Gene duplication
Tumor Cells, Cultured
Animals
Humans
Medicine
Tissue Distribution
Protein Kinase Inhibitors
Cell Proliferation
media_common
biology
business.industry
Antibodies, Monoclonal
Proto-Oncogene Proteins c-met
Xenograft Model Antitumor Assays
Blockade
Macaca fascicularis
Oncology
chemistry
Mutation
Cancer research
biology.protein
Female
Antibody
business
Tyrosine kinase
Subjects
Details
- ISSN :
- 15388514 and 15357163
- Volume :
- 20
- Database :
- OpenAIRE
- Journal :
- Molecular Cancer Therapeutics
- Accession number :
- edsair.doi.dedup.....81d6e8736c87f6f2e556c3b466b9e693